MX2018013509A - Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos. - Google Patents
Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos.Info
- Publication number
- MX2018013509A MX2018013509A MX2018013509A MX2018013509A MX2018013509A MX 2018013509 A MX2018013509 A MX 2018013509A MX 2018013509 A MX2018013509 A MX 2018013509A MX 2018013509 A MX2018013509 A MX 2018013509A MX 2018013509 A MX2018013509 A MX 2018013509A
- Authority
- MX
- Mexico
- Prior art keywords
- sequence
- polynucleotides
- optimized
- polynucleotides encoding
- reading frame
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se relaciona a polinucleótidos que comprenden una estructura de lectura abierta de nucleósidos enlazados que codifican interleucina-12 (IL12) humana, fragmentos funcionales de la misma y proteínas de fusión que comprenden IL12. En algunas modalidades, la estructura de lectura abierta se optimiza en secuencia. En modalidades particulares, la descripción proporciona polinucleótidos optimizados en secuencia que comprenden nucleótidos que codifican la secuencia de polipéptido de IL12 humana, o secuencias que tienen alta identidad de secuencia con aquellos polinucleótidos optimizados en secuencia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338483P | 2016-05-18 | 2016-05-18 | |
US201762443693P | 2017-01-07 | 2017-01-07 | |
PCT/US2017/033422 WO2017201350A1 (en) | 2016-05-18 | 2017-05-18 | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013509A true MX2018013509A (es) | 2019-03-28 |
Family
ID=58794205
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013509A MX2018013509A (es) | 2016-05-18 | 2017-05-18 | Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos. |
MX2022008602A MX2022008602A (es) | 2016-05-18 | 2018-11-05 | Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008602A MX2022008602A (es) | 2016-05-18 | 2018-11-05 | Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos. |
Country Status (22)
Country | Link |
---|---|
US (5) | US10646549B2 (es) |
EP (2) | EP3458083B1 (es) |
JP (2) | JP7246930B2 (es) |
KR (2) | KR20220159479A (es) |
CN (1) | CN109195621A (es) |
AU (1) | AU2017268397B2 (es) |
CA (1) | CA3024470A1 (es) |
DK (1) | DK3458083T3 (es) |
ES (1) | ES2941411T3 (es) |
FI (1) | FI3458083T3 (es) |
HR (1) | HRP20230050T1 (es) |
HU (1) | HUE061077T2 (es) |
IL (1) | IL262501A (es) |
LT (1) | LT3458083T (es) |
MX (2) | MX2018013509A (es) |
PL (1) | PL3458083T3 (es) |
PT (1) | PT3458083T (es) |
RS (1) | RS63912B1 (es) |
RU (1) | RU2769316C2 (es) |
SG (1) | SG11201809381XA (es) |
SI (1) | SI3458083T1 (es) |
WO (1) | WO2017201350A1 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CN105980401A (zh) | 2013-10-03 | 2016-09-28 | 现代治疗公司 | 编码低密度脂蛋白受体的多核苷酸 |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
EP4036079A3 (en) | 2015-12-22 | 2022-09-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
LT3458083T (lt) | 2016-05-18 | 2023-02-10 | Modernatx, Inc. | Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3551193A4 (en) * | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
EP3596041B1 (en) | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
EP3801562A4 (en) * | 2018-05-31 | 2022-06-29 | Beth Israel Deaconess Medical Center | Rna-aided immunotherapeutics |
US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
GB2606038B (en) | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
AU2019338535A1 (en) * | 2018-09-14 | 2021-04-15 | Modernatx, Inc. | Methods and compositions for treating cancer using mRNA therapeutics |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
WO2020146700A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
KR20210113655A (ko) | 2019-01-10 | 2021-09-16 | 얀센 바이오테크 인코포레이티드 | 전립선 신생항원 및 이의 용도 |
MX2021010995A (es) * | 2019-03-14 | 2021-12-10 | Engene Inc | Recubrimiento reversible de nanopartículas de quitosano-ácido nucleico y métodos para su uso. |
US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
CN109932511B (zh) * | 2019-03-22 | 2020-02-04 | 南昌大学第二附属医院 | 用于肝癌筛查的尿液外泌体磷脂标志物及其试剂盒 |
US20200325241A1 (en) * | 2019-04-11 | 2020-10-15 | Massachusetts Institute Of Technology | Novel chimeric antigen receptors and libraries |
SG11202112922WA (en) | 2019-05-22 | 2021-12-30 | Massachusetts Inst Technology | Circular rna compositions and methods |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
CA3168509A1 (en) * | 2020-02-19 | 2021-08-26 | Elias SAYOUR | Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
CN115297868B (zh) * | 2020-02-21 | 2024-04-12 | 联合治疗公司 | 用于编码核糖核酸的器官保护性表达和调节的组合物及方法 |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
KR20220166802A (ko) | 2020-04-09 | 2022-12-19 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 나노입자 조성물 |
CN116648510A (zh) | 2020-05-17 | 2023-08-25 | 贝林格尔.英格海姆国际有限公司 | 用于受调控基因治疗的病毒载体和核酸 |
US20230295257A1 (en) | 2020-07-24 | 2023-09-21 | Strand Therapeutics Inc. | Lipid nanoparticle comprising modified nucleotides |
US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
AU2022205679A1 (en) | 2021-01-08 | 2023-07-06 | Strand Therapeutics Inc. | Expression constructs and uses thereof |
US11524023B2 (en) * | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
AU2022268465A1 (en) * | 2021-05-06 | 2023-03-09 | Stemirna Therapeutics Co., Ltd. | A lipid |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
CN116829578A (zh) * | 2021-10-08 | 2023-09-29 | 苏州艾博生物科技有限公司 | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 |
EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
CN116179549A (zh) | 2021-12-08 | 2023-05-30 | 南京吉迈生物技术有限公司 | 通过5’utr序列变体修饰基因转录和翻译效率 |
CN114957027B (zh) * | 2022-01-13 | 2023-05-19 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023196988A1 (en) * | 2022-04-07 | 2023-10-12 | Modernatx, Inc. | Methods of use of mrnas encoding il-12 |
CN116535491B (zh) * | 2022-05-06 | 2024-03-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
CN114994331B (zh) * | 2022-05-17 | 2023-02-24 | 无锡科金生物科技有限公司 | 一种检测蛋白表达水平的试剂盒及其制备方法和应用 |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024020453A2 (en) * | 2022-07-20 | 2024-01-25 | Hdt Bio Corp. | Immune system modulators and uses thereof |
DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
US6140496A (en) | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
CA2268276A1 (en) | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Gene expression and delivery systems and uses |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
CA2309535A1 (en) | 1997-11-12 | 1999-05-20 | Brigham And Women's Hospital, Inc. | The translation enhancer element of the human amyloid precursor protein gene |
CA2641217A1 (en) | 1997-11-20 | 1999-06-03 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
KR100519895B1 (ko) | 1998-04-23 | 2005-10-13 | 다카라 바이오 가부시키가이샤 | Dna 의 합성방법 |
AU761520B2 (en) | 1998-09-15 | 2003-06-05 | Genetics Institute, Llc | Treatment of Kaposi's Sarcoma with IL-12 |
WO2000018778A1 (en) | 1998-09-29 | 2000-04-06 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
AU4050801A (en) | 2000-01-20 | 2001-07-31 | Unitectra Inc. | Intra-tumoral administration of il-12 encoding nucleic acid molecules |
AU3120601A (en) | 2000-01-28 | 2001-08-07 | Scripps Research Inst | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
ES2164011B1 (es) | 2000-02-25 | 2003-05-16 | Inst Cientifico Tecnol Navarra | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. |
EP1268759B1 (en) | 2000-03-15 | 2006-09-27 | Genexine Co., Ltd. | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
KR20020010206A (ko) | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신 |
EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
WO2003004685A2 (en) | 2001-07-03 | 2003-01-16 | University Of Utah Research Foundation | Soluble steroidal peptides for nucleic acid delivery |
EP2390329B1 (en) | 2001-09-28 | 2018-04-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
ATE427992T1 (de) | 2001-11-14 | 2009-04-15 | Toyo Boseki | Dna-synthesepromotoren, mit dna-polymerase assoziierte faktoren und nutzung davon |
CA2409775C (en) | 2001-12-03 | 2010-07-13 | F. Hoffmann-La Roche Ag | Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro |
AU2003228440B2 (en) | 2002-04-01 | 2008-10-02 | Walter Reed Army Institute Of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
US7595303B1 (en) | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
CA3031833C (en) | 2003-05-30 | 2022-07-26 | University Of South Florida | Uses of il-2 as a therapeutic medicament in combination with electroporation for the treatment of malignancies |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
EP1640018A1 (en) | 2004-09-24 | 2006-03-29 | Universität Zürich | Combinational therapy for treating cancer |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US7550264B2 (en) | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
KR20080025181A (ko) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법 |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
JP5225087B2 (ja) | 2005-08-24 | 2013-07-03 | ザ スクリプス リサーチ インスティチュート | 翻訳エンハンサーエレメント依存性のベクター系 |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
EA015338B1 (ru) | 2005-12-30 | 2011-06-30 | Мерк Патент Гмбх | ВАРИАНТЫ ИЛ-12p40 С УЛУЧШЕННОЙ СТАБИЛЬНОСТЬЮ |
EP2586455B1 (en) | 2006-01-05 | 2014-06-25 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP2487252B1 (en) | 2006-01-05 | 2014-10-15 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon cancer |
WO2007084364A2 (en) | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Improved il-12 for expression in mammalian cells |
KR101241477B1 (ko) | 2006-01-27 | 2013-03-08 | 엘지이노텍 주식회사 | 질화물 반도체 발광소자 및 그 제조 방법 |
EP2522746B1 (en) | 2006-03-02 | 2014-11-12 | The Ohio State University Research Foundation | MicroRNA expression profile associated with pancreatic cancer |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
ES2425416T3 (es) | 2006-11-01 | 2013-10-15 | The Ohio State University Research Foundation | Firma de expresión del microARN para predecir la supervivencia y la metástasis en el carcinoma hepatocelular |
US20090092974A1 (en) | 2006-12-08 | 2009-04-09 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
EP2207891B1 (en) | 2006-12-22 | 2012-07-25 | Archemix LLC | Materials and methods for the generation of transcripts comprising modified nucleotides |
US8765462B2 (en) | 2007-05-04 | 2014-07-01 | University Health Network | IL-12 immunotherapy for cancer |
WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
TWI359030B (en) | 2007-08-24 | 2012-03-01 | Univ Nat Taiwan | Treatment of cellular proliferative disorders |
ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
US20110086904A1 (en) | 2007-09-17 | 2011-04-14 | The Trustees Of The University Of Pennsylvania | GENERATION OF HYPERSTABLE mRNAs |
EP2399610A3 (en) * | 2007-09-24 | 2012-09-05 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
RU2524431C2 (ru) | 2007-09-26 | 2014-07-27 | Интрексон Корпорейшн | Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии |
AU2008329755A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | MicroRNA expression profiling and targeting in peripheral blood in lung cancer |
SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
CN102015027A (zh) | 2008-02-28 | 2011-04-13 | 俄亥俄州立大学研究基金会 | 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途 |
EP2279254B1 (en) * | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
WO2009140206A1 (en) | 2008-05-11 | 2009-11-19 | The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services | Improved expression of il-12 family heterodimers |
US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
CN102439169B (zh) | 2008-11-13 | 2014-11-19 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
PT4209510T (pt) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t |
EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
US20120264626A1 (en) | 2009-05-08 | 2012-10-18 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof |
ES2901627T3 (es) | 2009-06-10 | 2022-03-23 | Arbutus Biopharma Corp | Formulación lipídica mejorada |
ES2587963T3 (es) | 2009-07-31 | 2016-10-27 | Ethris Gmbh | ARN con una combinación de nucleótidos no modificados y modificados para la expresión de proteínas |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
ME03091B (me) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
WO2012009644A2 (en) | 2010-07-16 | 2012-01-19 | Arizona Board Of Regents | Methods to identify synthetic and natural rna elements that enhance protein translation |
WO2012038448A1 (en) | 2010-09-21 | 2012-03-29 | Riboxx Gmbh | Method for synthesizing rna using dna template |
WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
KR20120066952A (ko) | 2010-12-15 | 2012-06-25 | 주식회사 롤팩 | 7층 구조의 공압출 항균 진공포장 필름 및 그 제조방법 |
EP2651445A2 (en) | 2010-12-16 | 2013-10-23 | SPRNA GmbH | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
CA2831613A1 (en) * | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20140113978A1 (en) | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
EP2706690B1 (en) | 2011-05-02 | 2018-03-21 | LG Electronics Inc. | Method for transmitting/receiving data in wireless access system and base station for same |
EP2944961A1 (en) | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
DK2732052T3 (en) | 2011-07-15 | 2017-02-20 | Leo Pharma As | Diagnostic microRNA profiling in cutaneous T cell lymphoma (CTCL) |
US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
EP4015005A1 (en) | 2011-10-03 | 2022-06-22 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20150017121A1 (en) | 2011-10-11 | 2015-01-15 | Universitat Zurich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
JP6333730B2 (ja) | 2011-12-12 | 2018-05-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
EP2672197A1 (de) | 2012-06-06 | 2013-12-11 | Hörmann Energietechnik GmbH & Co. KG | Montageanordnung zur dachseitigen Montage von Flächenkörpern an einem Bauwerk |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
US20140020675A1 (en) | 2012-07-18 | 2014-01-23 | Chandrashekhar Sonwane | Solar receiver |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
CN102876684B (zh) * | 2012-09-17 | 2014-10-08 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
PT2922554T (pt) * | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
EP2929035A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
JP6352950B2 (ja) | 2013-03-08 | 2018-07-04 | ノバルティス アーゲー | 活性薬物の送達のための脂質と脂質組成物 |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
CN105142676B (zh) | 2013-03-14 | 2022-06-28 | 夏尔人类遗传性治疗公司 | Cftr mrna组合物以及相关方法和用途 |
AU2014239250A1 (en) | 2013-03-14 | 2015-08-27 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger RNA |
MX2015011945A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ, インコーポレイテッド | mRNAによってコードされる抗体を送達するための方法及び組成物 |
MX2015011943A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. |
EP2970940B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
HUE039189T2 (hu) | 2013-03-15 | 2018-12-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
WO2015024667A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Method for increasing expression of rna-encoded proteins |
PL3044234T3 (pl) | 2013-09-13 | 2020-10-19 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środków terapeutycznych i diagnostycznych |
JP6558699B2 (ja) | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン |
AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
ES2865699T3 (es) | 2013-10-22 | 2021-10-15 | Translate Bio Inc | Formulaciones de lípidos para la administración de ARN mensajero |
WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
US20150190506A1 (en) * | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US20160311879A1 (en) * | 2013-12-18 | 2016-10-27 | Intrexon Corporation | Single chain il-12 nucleic acids, polypeptides, and uses thereof |
CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
AU2014375402B2 (en) | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
RS63848B1 (sr) * | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
EP3326641B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
US10682401B2 (en) | 2015-05-19 | 2020-06-16 | Morphogenesis, Inc. | Multi-indication mRNA cancer immunotherapy |
US9636388B2 (en) | 2015-05-19 | 2017-05-02 | Morphogenesis, Inc. | Multi-indication mRNA cancer immunotherapy |
CA2998810A1 (en) * | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3205356A1 (en) | 2016-02-10 | 2017-08-16 | Onkoloski Institut Ljubljana | Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof |
EP3211000B1 (en) | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
LT3458083T (lt) | 2016-05-18 | 2023-02-10 | Modernatx, Inc. | Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
JP2019532648A (ja) | 2016-10-07 | 2019-11-14 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | がんの治療のための膜係留il−12を発現しているt細胞 |
-
2017
- 2017-05-18 LT LTEPPCT/US2017/033422T patent/LT3458083T/lt unknown
- 2017-05-18 EP EP17726458.7A patent/EP3458083B1/en not_active Revoked
- 2017-05-18 KR KR1020227040214A patent/KR20220159479A/ko not_active Application Discontinuation
- 2017-05-18 AU AU2017268397A patent/AU2017268397B2/en active Active
- 2017-05-18 FI FIEP17726458.7T patent/FI3458083T3/fi active
- 2017-05-18 CA CA3024470A patent/CA3024470A1/en active Pending
- 2017-05-18 ES ES17726458T patent/ES2941411T3/es active Active
- 2017-05-18 PL PL17726458.7T patent/PL3458083T3/pl unknown
- 2017-05-18 RS RS20230055A patent/RS63912B1/sr unknown
- 2017-05-18 RU RU2018144292A patent/RU2769316C2/ru active
- 2017-05-18 DK DK17726458.7T patent/DK3458083T3/da active
- 2017-05-18 PT PT177264587T patent/PT3458083T/pt unknown
- 2017-05-18 HU HUE17726458A patent/HUE061077T2/hu unknown
- 2017-05-18 KR KR1020187036222A patent/KR102469450B1/ko active IP Right Grant
- 2017-05-18 WO PCT/US2017/033422 patent/WO2017201350A1/en unknown
- 2017-05-18 JP JP2018560509A patent/JP7246930B2/ja active Active
- 2017-05-18 SI SI201731299T patent/SI3458083T1/sl unknown
- 2017-05-18 MX MX2018013509A patent/MX2018013509A/es unknown
- 2017-05-18 CN CN201780030730.8A patent/CN109195621A/zh active Pending
- 2017-05-18 HR HRP20230050TT patent/HRP20230050T1/hr unknown
- 2017-05-18 SG SG11201809381XA patent/SG11201809381XA/en unknown
- 2017-05-18 EP EP22204799.5A patent/EP4186518A1/en not_active Withdrawn
-
2018
- 2018-10-21 IL IL262501A patent/IL262501A/en unknown
- 2018-11-05 MX MX2022008602A patent/MX2022008602A/es unknown
- 2018-11-15 US US16/192,274 patent/US10646549B2/en active Active
-
2020
- 2020-04-07 US US16/842,300 patent/US11000573B2/en active Active
-
2021
- 2021-05-05 US US17/308,686 patent/US11311602B2/en active Active
-
2022
- 2022-04-15 US US17/721,583 patent/US11571463B2/en active Active
-
2023
- 2023-02-06 US US18/164,796 patent/US20240024422A1/en active Pending
- 2023-03-15 JP JP2023040409A patent/JP2023072056A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008602A (es) | Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos. | |
PH12017501347A1 (en) | Agonistic icos binding proteins | |
PH12016500388A1 (en) | Gitr antigen binding proteins | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
MX2019004810A (es) | Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos. | |
WO2018231990A3 (en) | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE | |
MX2023013729A (es) | Receptores quimericos de flt3 y metodos de uso de los mismos. | |
MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
MX2022008508A (es) | Enzimas y aplicaciones de las mismas. | |
MX2021003765A (es) | Proteínas il-12 de fusión a fc heterodimérico. | |
MX2019000514A (es) | Anticuerpos de tgfb, métodos, y usos. | |
PH12018501025A1 (en) | Improved tnf binders | |
WO2015095249A8 (en) | Single chain il-12 nucleic acids, polypeptids, and uses thereof | |
MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
BR112018068103A2 (pt) | anticorpos gitr, métodos e usos | |
SA521422495B1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
MX2019003077A (es) | Anticuerpos novedosos contra el factor xi y sus usos. | |
ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
BR112015019719A2 (pt) | Proteínas melhoradas de ligação ao tnf | |
MX2020011298A (es) | Composiciones de antígeno micobacteriano y métodos de uso. | |
MA45027B1 (fr) | Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations | |
MX2023012266A (es) | Un fab anti-tslp con estabilidad mejorada. |